Table of Content

Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing Research and Development
4.1.1.2. Growing Cases of Uveitis
4.1.1.3. Market Strategies
4.1.2. Restraints
4.1.2.1. High Cost
4.1.2.2. Drug Side Effects
4.1.2.3. Stringent Regulatory Bodies
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Epidemiological Analysis
5.3. Research and Developments
5.4. Pipeline Analysis
5.5. Supply Chain Analysis
5.6. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
7.1.2. Market Attractiveness Index, By Treatment Type Segment
7.2. Corticosteroids
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Immunosuppressant
7.4. Monoclonal Antibodies
7.5. Antibiotics
7.6. Others
8. By Disease Type
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
8.1.2. Market Attractiveness Index, By Disease Type Segment
8.2. Anterior Uveitis
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Posterior Uveitis
8.4. Intermediate Uveitis
8.5. Panuveitis
9. By Cause
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause Segment
9.1.2. Market Attractiveness Index, By Cause Segment
9.2. Non-Infectious
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Infectious
10. By Distribution Channels
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channels Segment
10.1.2. Market Attractiveness Index, By Distribution Channels Segment
10.2. Hospital Pharmacies
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. The U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Disease Type
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Cause
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
13. Company Profiles
13.1. Bausch & Lomb Incorporated
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Santen Pharmaceutical Co., Ltd
13.3. AbbVie Inc.
13.4. Eyegate Pharmaceuticals, Inc.
13.5. Regeneron Pharmaceuticals
13.6. Eyepoint Pharmaceuticals Inc.
13.7. Alimera Sciences, Inc.
13.8. Clearside Biomedical, Inc.
13.9. Aldeyra Therapeutics, Inc
LIST NOT EXHAUSTIVE
14. DataM
14.1. Appendix
14.2. About Us and Services
14.3. Contact